Anti-IL-23 monoclonal antibody - Merck

Drug Profile

Anti-IL-23 monoclonal antibody - Merck

Latest Information Update: 08 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 08 Aug 2011 No development reported - Phase-I for Inflammation in USA (Parenteral)
  • 04 Nov 2009 Schering-Plough combines with Merck & Co and retains the name Merck & Co
  • 01 Dec 2008 Phase-I clinical trials in Inflammation in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top